Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial.
Simeon SchietzelLia BallyGrazia CereghettiNicolas FallerMatthias B MoorBruno VogtFelix RintelenS TrelleDaniel FusterPublished in: BMJ open (2022)
NCT04911660; Pre-results.